Zydus Cadila gets USFDA nod to market migraine drug
New Delhi: Drug firm Cadila Healthcare said Zydus Cadila has received an approval from the US health regulator to market Eletriptan Hydrobromide tablets used in treatment of migraine.
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide tablets, 20 mg (base) and 40 mg (base)", Cadila Healthcare said in a statement.
The drug used in the treatment of migraine, will be produced at the groups formulations manufacturing facility at the Pharma SEZ in Ahmedabad, it added.
The group currently has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd